Compare Baroda BNP Paribas Health and Wellness Fund vs ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund
Risk | Very High | Very High |
Rating | - | 5.0 |
Min SIP Amount | ₹500 | ₹100 |
Expense Ratio | 2.33 | 1.86 |
NAV | ₹9.32 | ₹38.69 |
Fund Started | 09 Jun 2025 | 25 Jun 2018 |
Fund Size | ₹611.32 Cr | ₹6455.55 Cr |
Exit Load | Exit Load for units in excess of 10% of the investment,1% will be charged for redemption within 1 year. | Exit load of 1% if redeemed within 15 days. |
Risk
Very High
Very High
Rating
-
5.0
Min SIP Amount
₹500
₹100
Expense Ratio
2.33
1.86
NAV
₹9.32
₹38.69
Fund Started
09 Jun 2025
25 Jun 2018
Fund Size
₹611.32 Cr
₹6455.55 Cr
Exit Load
Exit Load for units in excess of 10% of the investment,1% will be charged for redemption within 1 year.
Exit load of 1% if redeemed within 15 days.
1 Year | - | 1.79% |
3 Year | - | 26.35% |
5 Year | - | 16.49% |
1 Year
-
1.79%
3 Year
-
26.35%
5 Year
-
16.49%
Equity | 96.78% | 97.87% |
Cash | -0.31% | 2.13% |
Equity
96.78%
97.87%
Cash
-0.31%
2.13%
Top 10 Holdings |
|
|
Top 10 Holdings
Sun Pharmaceutical Industries Ltd. | 8.99% |
Mankind Pharma Ltd. | 7.00% |
Cipla Ltd. | 6.51% |
Max Healthcare Institute Ltd. | 6.28% |
Apollo Hospitals Enterprise Ltd. | 6.00% |
Aster DM Healthcare Ltd. | 4.90% |
Abbott India Ltd. | 4.82% |
Divi's Laboratories Ltd. | 4.24% |
Torrent Pharmaceuticals Ltd. | 3.96% |
Astrazeneca Pharma India Ltd. | 3.84% |
Sun Pharmaceutical Industries Ltd. | 12.05% |
Cipla Ltd. | 7.90% |
Dr. Reddy's Laboratories Ltd. | 7.82% |
Divi's Laboratories Ltd. | 7.10% |
Mankind Pharma Ltd. | 6.44% |
Lupin Ltd. | 5.78% |
Aurobindo Pharma Ltd. | 5.19% |
Alkem Laboratories Ltd. | 3.66% |
Cohance Lifesciences Ltd. | 3.01% |
Syngene International Ltd. | 2.98% |
Name | Sanjay Chawla | - |
Start Date | 09 Jun 2025 | - |
Name
Sanjay Chawla
-
Start Date
09 Jun 2025
-
Description | The scheme is to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies. The Scheme does not guarantee/indicate any returns. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 09 Jun 2025 | 25 Jun 2018 |
Description
The scheme is to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies. The Scheme does not guarantee/indicate any returns.
The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.
Launch Date
09 Jun 2025
25 Jun 2018